Search Results - "Youssoufian, H"

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours by Schöffski, P, Adkins, D, Blay, J.-Y, Gil, T, Elias, A.D, Rutkowski, P, Pennock, G.K, Youssoufian, H, Gelderblom, H, Willey, R, Grebennik, D.O

“…Abstract Background Cixutumumab (IMC-A12), a fully human immunoglobulin G1 (IgG1) monoclonal antibody, exerts preclinical activity in several sarcoma models…”
Get full text

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441) by Hammel, P., Feliu, J., Parner, V., Berardi, R., Van Cutsem, E., Greil, R., Wasan, H., Metges, J., Nygren, P., Osterlund, P., Seufferlein, T., Creemers, G., Biswas-Baldwin, N., Youssoufian, H., Gupta, A., Salesse, S., Dion, H., El-Hariry, I., Hidalgo, M.

Get full text

Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors by Coward, J., Lemech, C., Meniawy, T., Dupont, C.D., Gonzalez, A.M., Lim, M., Savitsky, D., Carini, M., Hu, S., Shebanova, O., Dow, E., Ortuzar, W., Buell, J.S., Stein, R.B., Youssoufian, H.

Get full text

Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer by Drescher, C., Moore, K.N., Liu, J.F., O’Malley, D.M., Wang, E.W., Wang, J.S.-Z., Subbiah, V., Wilky, B.A., Yuan, G., Dupont, C.D., Gonzalez, A.M., Savitsky, D., Coulter, S., Shebanova, O., Dow, E., Ortuzar, W., Buell, J.S., Stein, R.B., Youssoufian, H.

Get full text

Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy by Wilky, B.A., Kumthekar, P., Wesolowski, R., Hwang, J.J., Park, S.I., Yuan, G., Dupont, C.D., Lim, M., Shebanova, O., Cuillerot, J.-M., Dow, E., Ortuzar, W., Raizer, J.J., Drouin, E., Wilson, N., Gonzalez, A.M., Goldberg, J.M., Buell, J.S., Stein, R.B., Youssoufian, H.

Get full text

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial by Horwitz, S.M., Foss, F.M., Porcu, P., Moskowitz, A., Mehta‐Shah, N., Jacobsen, E., Khodadoust, M.S., Kim, Y.H., Weinstock, D., Lustgarten, S., Baglio, M., Youssoufian, H., Brammer, J.

Get full text

AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES by Flinn, I.W., Davids, M.S., Hillmen, P., Montillo, M., Delgado, J., Kuss, B.J., Tam, C.S., Jäger, U., Ghia, P., Stilgenbauer, S., Lustgarten, S., Weaver, D.T., Youssoufian, H., Cymbalista, F.

Get full text

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL by Ghia, P., Flinn, I.W., Lamanna, N., Montillo, M., Illés, Á., Etienne, G., Delgado, J., Kuss, B.J., Tam, C.S., Offner, F., Bosch, F., Davids, M.S., Jäger, U., Cymbalista, F., Weaver, D.T., Lustgarten, S., Youssoufian, H., Stilgenbauer, S.

Get full text

195 Intramuscular Electroporation of an Optimized RheoSwitch®-regulated Interferon Alpha Plasmid Transgene Shows Long Term Persistence in Vivo: Implications for Therapy of Cancer by Agarwal, P, Chan, T, Roeth, J, Reed, C, Yang, Z, Barrett, J.A, Khazi, F, Youssoufian, H, Herberman, R, Fogler, W.E

Get full text

Localization of Fanconi Anemia C Protein to the Cytoplasm of Mammalian Cells by Youssoufian, Hagop

“…Features of chromosomal aberrations, hypersensitivity to DNA crosslinking agents, and predisposition to malignancy have suggested a fundamental anomaly of DNA…”
Get full text

DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA by Zinzani, P., Wagner‐Johnston, N., Miller, C., Ardeshna, K., Tertreault, S., Assouline, S., Mayer, J., Passamonti, F., Lunin, S., Pettitt, A., Nagy, Z., Tournilhac, O., Abou‐Nassar, K., Crump, M., Jacobsen, E., De Vos, S., Youssoufian, H., Porter, J., Prado, S., Flinn, I.

Get full text

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL by Jacobsen, E., Ďuraš, J., Ardeshna, K., Cherry, M., Offner, F., Mayer, J., Bijou, F., Tani, M., Musuraca, G., Merli, M., Marasca, R., Weaver, D.T., Lustgarten, S., Youssoufian, H., Zinzani, P.

Get full text

Fanconi anaemia proteins: Major roles in cell protection against oxidative damage by Pagano, Giovanni, Youssoufian, Hagop

“…Fanconi anaemia (FA) is a cancer‐prone genetic disorder that is characterised by cytogenetic instability and redox abnormalities. Although rare subtypes of FA…”
Get full text

Structure, function, and activation of the erythropoietin receptor by HAGOP YOUSSOUFIAN, LONGMORE, G, NEUMANN, D, YOSHIMURA, A, LODISH, H. F

Get full text

Fanconi anemia and breast cancer: what's the connection? by Youssoufian, Hagop

“…BRCA1 activity may be regulated by the ubiquitin-modified form of the Fanconi anemia D2 protein. Other proteins involved in DNA repair and genomic stability…”
Get full text

943TiP PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) by Saba, N., Youssoufian, H., Cohen, E., Singh, J., Makris, L., Perdomini, M., MacIntyre, S., Denker, A.

Get full text

Cell cycle-dependent expression and nucleolar localization of hCAP-H by Cabello, O A, Eliseeva, E, He, W G, Youssoufian, H, Plon, S E, Brinkley, B R, Belmont, J W

“…Condensin is a conserved 13S heteropentamer composed of two nonidentical structural maintenance of chromosome (SMC) family proteins, in Xenopus XCAP-C and…”
Get full text

Localization of Anticoagulantly Active Heparan Sulfate Proteoglycans in Vascular Endothelium: Antithrombin Binding on Cultured Endothelial Cells and Perfused Rat Aorta by de Agostini, Ariane I., Watkins, Simon C., Slayter, Henry S., Youssoufian, Houry, Rosenberg, Robert D.

“…We have studied the interaction of 125 I-antihrombin (125 I- AT) with microvascular endothelial cells (RFPEC) to localize the cellular site of anticoagulantly…”
Get full text

Suppression of apoptosis in hematopoietic factor-dependent progenitor cell lines by expression of the FAC gene by CUMMING, R. C, LIU, J. M, YOUSSOUFIAN, H, BUCHWALD, M

“…Fanconi anemia (FA) is a genetically heterogeneous, inherited blood disorder characterized by bone marrow failure, congenital malformations, and a…”
Get full text

The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains by D'ANDREA, A. D, YOSHIMURA, A, YOUSSOUFIAN, H, ZON, L. I, JAH-WON KOO, LODISH, H. F

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text